Heat Bio’s Pelican subsidiary strikes deal with Selexis to advance cancer immunotherapy – WRAL Tech Wire
WRAL Tech Wire |
Heat Bio's Pelican subsidiary strikes deal with Selexis to advance cancer immunotherapy
WRAL Tech Wire Durham, N.C. — Pelican Therapeutics, a subsidiary of Durham-based Heat Biologics Inc., has entered a service agreement with Geneva-based Selexis SA to advance development of Pelican's cancer-fighting therapy candidates. Pelican intends to leverage … |
